UK patent changes could attract more new drug trials
This article was originally published in Scrip
Executive Summary
New UK legislation is expected to come into force in October that will level the playing field between originator and generic pharmaceutical companies in the area of clinical trials, and could help to make the UK more attractive as a location to conduct studies of new drugs.